EUVIMEDEUVIMED entdecken
Vergleichsstudie

Management of advanced basal cell carcinoma with hedgehog inhibitors: a real-world prospective comparative study

Federico Venturi, Biancamaria Zuccaro, Gabriella Perillo, Giovanni Cecchi, Aurora Gaeta, Sara Gandini, Vincenzo De Giorgi iD

Clinical and Experimental Dermatology · 2025

DOI: 10.1093/ced/llaf383 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical and Experimental Dermatology, 2025. Verfasst von Federico Venturi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy. Hauptthemen laut MEDLINE: Basal Cell Carcinoma, Pyridines, Anilides, Skin Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hedgehog inhibitors (HHIs) should be offered to patients with advanced basal cell carcinoma (BCC) as a first-line treatment. Two systemic HHIs are currently available: sonidegib and vismodegib.

Objectives

As there is no head-to-head trial of sonidegib vs. vismodegib and very few comparative studies have been published, we aimed to prospectively describe our long-term approach to managing advanced BCC based on our 10 years of experience with HHIs.

Methods

We undertook a prospective, monocentric and descriptive study in Florence, Italy. Patients who were treated with sonidegib and/or vismodegib for advanced BCC according to the European Association of Dermato-Oncology staging system were included from January 2013 to December 2023. Epidemiological, efficacy and safety data were collected.

Results

The study population consisted of 66 patients with a clinicopathologically confirmed diagnosis of advanced BCC. Of the 66 patients, 40 (61%) were treated with vismodegib, 19 (29%) received sonidegib and 7 (11%) were switched to sonidegib after vismodegib discontinuation. Among the 40 evaluable vismodegib-treated patients, the overall response rate (ORR) was 65%, with complete response (CR) in 28% of cases. The disease control rate was 85%. Among the 19 evaluable patients treated with sonidegib, the ORR and CR rates were 89% and 37%, respectively. Regarding patients who switched from vismodegib to sonidegib (mainly patients who had adverse events with vismodegib previously), the ORR was 71%, with CR in 43% of cases.

Conclusions

The efficacy demonstrated by sonidegib is greater than reported in the pivotal studies, with an ORR of 89% (vs. 60.6%), a CR rate of 37% (vs. 22.7%) and a PR rate of 53% (vs. 37.9%). Another element of innovation was the analysis of the subgroup of patients who switched from vismodegib to sonidegib, with an ORR of 71% (CR 43%, PR 29%). This, in relation to the possibility of developing resistance during therapy with HHIs, represents a promising result, suggesting a maintenance of effectiveness of the target therapy even in patients who are not naive to it.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Basal Cell CarcinomaPyridinesAnilidesSkin NeoplasmsHedgehog ProteinsAntineoplastic AgentsBiphenyl CompoundsHumansFemaleMaleProspective StudiesAgedMiddle AgedAged, 80 and overAdultItalyTreatment Outcome

Substanzen

HhAntag691PyridinessonidegibAnilidesHedgehog ProteinsAntineoplastic AgentsBiphenyl Compounds

Autor:innen und Institutionen

  • Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy.
  • Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, Bologna, Italy.
  • Department of Experimental Oncology, European Institute of Oncology, IRCCS, Milan, Italy.
  • Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy.
  • Cancer Research 'Attilia Pofferi' Foundation, Pistoia, Italy.

ORCID-Profile: Vincenzo De Giorgi

Zitieren

APA

Venturi, F., Zuccaro, B., Perillo, G., Cecchi, G., Gaeta, A., Gandini, S., & De Giorgi, V. (2025). Management of advanced basal cell carcinoma with hedgehog inhibitors: a real-world prospective comparative study. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llaf383

Vancouver

Venturi F, Zuccaro B, Perillo G, Cecchi G, Gaeta A, Gandini S, et al. Management of advanced basal cell carcinoma with hedgehog inhibitors: a real-world prospective comparative study. Clinical and Experimental Dermatology. 2025. doi:10.1093/ced/llaf383

BibTeX
@article{Venturi2025,
  author = {Venturi, Federico and Zuccaro, Biancamaria and Perillo, Gabriella and Cecchi, Giovanni and Gaeta, Aurora and Gandini, Sara and De Giorgi, Vincenzo},
  title = {Management of advanced basal cell carcinoma with hedgehog inhibitors: a real-world prospective comparative study},
  journal = {Clinical and Experimental Dermatology},
  year = {2025},
  doi = {10.1093/ced/llaf383}
}
Kostenlos starten →